Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Risk factors of vitamin K antagonist overcoagulation.

Marie I, Leprince P, Menard JF, Tharasse C, Levesque H.

QJM. 2012 Jan;105(1):53-62. doi: 10.1093/qjmed/hcr136. Epub 2011 Aug 31.

PMID:
21880698
2.

Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.

Cadiou G, Varin R, Levesque H, Grassi V, Benichou J, Tiret I, Dieu B, Lecam-Duchez V, Borg JY, Muller JM, Benhamou Y, Marie I.

Thromb Haemost. 2008 Oct;100(4):685-92.

PMID:
18841293
3.

Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?

Steib A, Barre J, Mertes M, Morel MH, Nathan N, Ozier Y, Treger M, Samama CM.

J Thromb Haemost. 2010 Mar;8(3):499-503. doi: 10.1111/j.1538-7836.2009.03685.x. Epub 2009 Nov 12.

4.

Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.

Karrowni W, Wang TY, Chen AY, Thomas L, Saucedo JF, El Accaoui RN.

Heart. 2015 Feb;101(4):264-70. doi: 10.1136/heartjnl-2014-305931. Epub 2014 Oct 21.

PMID:
25336230
5.

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin.

Malato A, Saccullo G, Lo Coco L, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S.

J Thromb Haemost. 2010 Jan;8(1):107-13. doi: 10.1111/j.1538-7836.2009.03649.x. Epub 2009 Oct 11.

6.

Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome.

Halbritter K, Beyer-Westendorf J, Nowotny J, Pannach S, Kuhlisch E, Schellong SM.

J Thromb Haemost. 2013 Apr;11(4):651-9. doi: 10.1111/jth.12148.

7.

Treatment with vitamin K antagonists: frequency of indications and appropriateness of continuation.

van Der Heijden JF, Remkes MG, Büller HR, Vermeulen M.

Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):111-4.

PMID:
12372923
8.

Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.

Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics.

Circulation. 2011 Aug 16;124(7):824-9. doi: 10.1161/CIRCULATIONAHA.110.007864. Epub 2011 Aug 1.

10.

[Major closed-space bleeding in patients on anticoagulation with acenocoumarol (TAO) or non-fractionned heparin(HS): a case-control study].

Martínez Lacasa J, Juan N, Juliá J, Rodríguez-Carballeira M, de Diego I, Soto R, Garau J.

An Med Interna. 2008 Jan;25(1):9-14. Spanish.

PMID:
18377188
11.

Approaches to optimal dosing of vitamin K antagonists.

Witt DM.

Semin Thromb Hemost. 2012 Oct;38(7):667-72. doi: 10.1055/s-0032-1324713. Epub 2012 Aug 14. Review.

PMID:
22893509
12.

Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Pautas E, Gouin-Thibault I, Debray M, Gaussem P, Siguret V.

Drugs Aging. 2006;23(1):13-25. Review.

PMID:
16492066
13.

Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases.

Denas G, Marzot F, Offelli P, Stendardo A, Cucchini U, Russo R, Nante G, Iliceto S, Pengo V.

J Thromb Thrombolysis. 2009 Apr;27(3):340-7. doi: 10.1007/s11239-008-0211-4. Epub 2008 Mar 13.

PMID:
18338109
14.

Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.

Gerotziafas GT, Dupont C, Spyropoulos AC, Hatmi M, Samama MM, Kiskinis D, Elalamy I.

Thromb Haemost. 2009 Jul;102(1):42-8. doi: 10.1160/TH08-10-0653.

PMID:
19572066
15.
16.

Is early antithrombotic therapy necessary after tissue mitral valve replacement?

Colli A, D'Amico R, Mestres CA, Pomar JL, Cámara ML, Ruyra X, Mulet J.

J Heart Valve Dis. 2010 Jul;19(4):405-11.

PMID:
20845885
17.

Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.

Veeger NJ, Piersma-Wichers M, Meijer K, Hillege HL.

Br J Haematol. 2011 May;153(4):508-14. doi: 10.1111/j.1365-2141.2011.08656.x. Epub 2011 Mar 21.

PMID:
21418182
18.
19.

Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.

Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio AM.

Arch Intern Med. 2010 Apr 12;170(7):609-16. doi: 10.1001/archinternmed.2010.49.

PMID:
20386004
20.

Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists.

Mathieu E, Van Dreden P, Aulagnier J, Grusse M, Dreyfus JF, François D, Vasse M.

Thromb Res. 2016 Jan;137:36-40. doi: 10.1016/j.thromres.2015.11.028. Epub 2015 Nov 22.

PMID:
26632514

Supplemental Content

Support Center